Infliximab injectable solution is available as brand-name drugs. It’s not available in a generic version. Brand names: Remicade, Inflectra, Renflexis. Infliximab comes in an injectable solution for ...

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. After previously discontinuing infliximab, 35% of ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Learn everything you need to know about Infliximab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) survey was undertaken in early 2002 to capture information about current clinical practice using infliximab in children with GVHD to plan a ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Infliximab and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease (see section 1.6) whose disease has not responded to ...